Journal
CANCER BIOLOGY & THERAPY
Volume 18, Issue 12, Pages 990-999Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15384047.2017.1394542
Keywords
ellagic acid; luteolin; pomegranate fruit juice; ovarian cancer; MMP2; MMP9
Categories
Funding
- China Scholarship Council (CSC) [201508230143]
- Fundamental Research Funds for the Provincial Universities [2017JCZX57]
- National Natural Science Foundation of China (NSFC) [NSFC30970119, 81030029, 81271786]
Ask authors/readers for more resources
Ovarian cancer is the third most common cancer in the female reproductive organs and epithelial ovarian cancer has the highest lethality of all gynecological cancers. Pomegranate fruit juice (PFJ) has been shown to inhibit the growth of several types of cancer other than ovarian cancer. In this study, we exposed the ovarian cancer cell line A2780 to PFJ and two of its components (ellagic acid and luteolin). MTT and wound healing assays demonstrated that all three treatments suppressed the proliferation and migration of the ovarian cancer cells. In addition, western blotting and ELISA assays showed that the expression levels of MMP2 and MMP9 gradually decreased after treatment with increasing concentrations of ellagic acid and luteolin. To confirm our findings in the in vitro experiments, we used another ovarian cancer cell line, ES-2, in nude mice experiments. All three treatments inhibited tumor growth without obvious side-effects. Furthermore, compared with the control group, the expression levels of MMP2 and MMP9 were depressed. Ellagic acid induced a greater effect than luteolin, suggesting that ellagic acid might be a promising candidate for further preclinical testing for treatment of human ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available